Cancer is a leading cause of death globally,
claiming about 9.6 million lives and approximately 420 million new cases of
cancer will be diagnosed in the world by the year 2025. The aim of this study
was to synthesize and computationally evaluate pharmacological potential of some
derivatives of 9-amino-3-phenylacridone, as topoisomerase II (Topo II)
inhibitors. In this study, 10
derivatives of 3-phenyl-9-aminoacridone were chemically synthesized and
characterized, and the potential pharmacological indications of these compounds
were computationally predicted by methods such as ADMET prediction, molecular
target prediction and molecular docking. The results showed that two
derivatives (58e and 58j) were non-permeant of blood-brain barrier, and this property was found similar to that of
amsacrine and etoposide. The results of molecular docking of the ten
derivatives of 3-phenyl-9-aminoacridone that were synthesized in this
work showed that the synthetic compounds (58a-j) and the standard drugs have
overall best binding affinities for human acetylcholine esterase than
butyrylcholinesterase, and overall best binding affinities for human topoIIα than human
topoIIβ. Overall,
the results of this study suggest that the synthetic compounds 58a, 58c, 58f,
58g, and 58i could probably inhibit topo IIα by catalytic inhibition as seen with amsacrine, but only 58b and 58e possessed
DNA non-intercalation properties as seen with etoposide, serving as topo II
poison. In conclusion, this study showed that 3-phenyl-9-aminoacridone
derivatives are potential inhibitor of topoIIα/β both by catalytic inhibition and
poison as non-intercalator of DNA.
References
[1]
Sitki-Copur, M. (2019) State of Cancer Research around the Globe. Oncology Journal, 33, 181-185.
[2]
Saini, A., Kumar, M., Bhatt, S., Saini, V. and Malik, A. (2020) Cancer Causes and Treatments. International Journal of Pharmaceutical Sciences and Research, 11, 3121-3134.
[3]
Bray, F. and Moller, B. (2006) Predicting the Future Burden of Cancer. Nature Reviews Cancer, 6, 63-74. https://doi.org/10.1038/nrc1781
[4]
Czerwinska, P., Mazurek, S. and Wiznerowicz, M. (2017) The Complexity of TRIM28 Contribution to Cancer. Journal of Biomedical Science, 24, Article No. 63. https://doi.org/10.1186/s12929-017-0374-4
[5]
Okoro, C.O. and Fatoki, T.H. (2023) A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents. International Journal of Molecular Sciences, 24, Article 2532. https://doi.org/10.3390/ijms24032532
[6]
Ertan-Bolelli, T. and Bolelli, K. (2019) Discovery of New DNA Topoisomerase II Inhibitors Using Structure Based Virtual Screening Method. Journal of the Turkish Chemical Society: Section A—Chemistry, 6, 71-78.
[7]
Adeniran, O.Y., Metibemu, A.O. and Boboye, S.O. (2021) Virtual High-Throughput Screening (VHTS), Three-Dimensional Quantitative Structure-Activity and Relationship (3D-QSAR) and Molecular Docking Studies of Novel Phytoinhibtors of Topoisomerase II α. GSC Biological and Pharmaceutical Sciences, 15, 72-82. https://doi.org/10.30574/gscbps.2021.15.2.0099
[8]
Oyedele, O.S., Bogan, D.N. and Okoro, C.O. (2020) Synthesis, Biological Evaluation and Virtual Screening of Some Acridone Derivatives as Potential Anticancer Agents. Bioorganic & Medicinal Chemistry, 28, Article ID: 115426. https://doi.org/10.1016/j.bmc.2020.115426
[9]
Daina, A., Michielin, O. and Zoete, V. (2017) SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. Scientific Report, 7, Article No. 42717. https://doi.org/10.1038/srep42717
[10]
Pires, D.E., Blundell, T.L. and Ascher, D.B. (2015) pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry, 58, 4066-4072. https://doi.org/10.1021/acs.jmedchem.5b00104
[11]
Kuhn, M., von Mering, C., Campillos, M., Jensen, L.J. and Bork, P. (2008) STITCH: Interaction Networks of Chemicals and Proteins. Nucleic Acids Research, 36, D684-D688. https://doi.org/10.1093/nar/gkm795
[12]
Fatoki, T., Chukwuejim, S., Ibraheem, O., Oke, C., Ejimadu, B., Olaoye, I., Oyegbenro, O., Salami, T., Basorun, R., Oluwadare, O. and Salawudeen, Y. (2022) Harmine and 7,8-Dihydroxyflavone Synergistically Suitable for Amyotrophic Lateral Sclerosis Management: An in Silico Study. Research Results in Pharmacology, 8, 49-61. https://doi.org/10.3897/rrpharmacology.8.83332
[13]
Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S. and Olson, A.J. (2009) AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. Journal of Computational Chemistry, 30, 2785-2791. https://doi.org/10.1002/jcc.21256
[14]
Trott, O. and Olson, A.J. (2010) AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading. Journal of Computational Chemistry, 31, 455-461. https://doi.org/10.1002/jcc.21334
[15]
Eberhardt, J., Santos-Martins, D., Tillack, A.F. and Forli, S. (2021) AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. Journal of Chemical Informatics and Modelling, 61, 3891-3898. https://doi.org/10.1021/acs.jcim.1c00203
[16]
Tao, A., Huang, Y., Shinohara, Y., Caylor, M.L., Pashikanti, S. and Xu, D. (2019) ezCADD: A Rapid 2D/3D Visualization-Enabled Web Modeling Environment for Democratizing Computer-Aided Drug Design. Journal of Chemical Informatics and Modelling, 59, 18-24. https://doi.org/10.1021/acs.jcim.8b00633
Pergolizzi, M., Bizzozero, L., Maione, F., Maldi, E., Isella, C., Macagno, M., Mariella, E., Alberto Bardelli, A., Medico, E., Marchio, C., Serini, G., Di Nicolantonio, F., Bussolino, F. and Arese, M. (2022) The Neuronal Protein Neuroligin 1 Promotes Colorectal Cancer Progression by Modulating the APC/β-Catenin Pathway. Journal of Experimental and Clinical Cancer Research, 41, Article No. 266. https://doi.org/10.1186/s13046-022-02465-4
[19]
Richbart, S.D., Merritt, J.C., Nolan, N.A. and Dasgupta, P. (2021) Acetylcholinesterase and Human Cancers. Advances in Cancer Research, 152, 1-66. https://doi.org/10.1016/bs.acr.2021.05.001
[20]
Hunter, A.J., Murray, T.K., Jones, J.A., Cross, A.J. and Green A.R. (1989) The Cholinergic Pharmacology of Tetrahydroaminoacridine in vivo and in vitro. British Journal of Pharmacology, 98, 79-86. https://doi.org/10.1111/j.1476-5381.1989.tb16865.x
[21]
Sabolová, D., Kristian, P. and Kožurková, M. (2018) Multifunctional Properties of Novel Tacrine Congeners: Cholinesterase Inhibition and Cytotoxic Activity. Journal of Applied Toxicology, 38, 1377-1387. https://doi.org/10.1002/jat.3622
[22]
Konkolová, E., Hudácová, M., Hamulaková, S., Jendželovsky, R., Vargová, J., Ševc, J., Fedorocko, P. and Kožurková, M. (2021) Tacrine-Coumarin Derivatives as Topoisomerase Inhibitors with Antitumor Effects on A549 Human Lung Carcinoma Cancer Cell Lines. Molecules, 26, Article 1133. https://doi.org/10.3390/molecules26041133
[23]
Lazarevic-Pasti, T., Leskovac, A., Momic, T., Petrovic, S. and Vasic, V. (2017) Modulators of Acetylcholinesterase Activity: From Alzheimer’s Disease to Anti-Cancer Drugs. Current Medicinal Chemistry, 24, 3283-3309. https://doi.org/10.2174/0929867324666170705123509
[24]
Roldan-Pena, J.M., Alejandre-Ramos, D., Lopez, O., Maya, I., Lagunes, I., Padron, J.M., Pena-Altamira, L.E., Bartolini, M., Monti, B., Bolognesi, M.L. and Fernandez-Bolanos, J.G. (2017) New Tacrine Dimers with Antioxidant Linkers as Dual Drugs: Anti-Alzheimer’s and Antiproliferative Agents. European Journal of Medicinal Chemistry, 138, 761-773. https://doi.org/10.1016/j.ejmech.2017.06.048
[25]
Solarova, Z., Kello, M., Hamulakova, S., Ladislav, M. and Solar, P. (2018) Anti-Cancer Effect of Tacrine-Coumarin Derivatives on Diverse Human and Mouse Cancer Cell Lines. Acta Chimica Slovenica, 65, 875-881. https://doi.org/10.17344/acsi.2018.4519
[26]
Okten, S., Aydin, A. and Tutar, A. (2019) Determination of Anticancer and Antibacterial Activities of Disubstituted Tacrine Derivatives. Sakarya University Journal of Science, 23, 824-830.
[27]
Janockova, J., Plsikova, J., Koval, J., Jendzelovsky, R., Mikes, J., Kasparkova, J., Brabec, V., Hamulakova, S., Fedorocko, P. and Kozurkova, M. (2015) Tacrine Derivatives as Dual Topoisomerase I and II Catalytic Inhibitors. Bioorganic Chemistry, 59, 168-176. https://doi.org/10.1016/j.bioorg.2015.03.002
[28]
Skok, Z., Zidar, N., Kikelj, D. and Ilas, J. (2020) Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. Journal of Medicinal Chemistry, 63, 884-904. https://doi.org/10.1021/acs.jmedchem.9b00726
[29]
Singh, I., Luxami, V., Choudhury, D. and Paul, K. (2022) Synthesis and Photobiological Applications of Naphthalimide-Benzothiazole Conjugates: Cytotoxicity and Topoisomerase IIα Inhibition. RSC Advances, 12, 483-497. https://doi.org/10.1039/D1RA04148G
[30]
Li, A.L., Hao, Y., Wang, W.Y., Liu, Q.S., Sun, Y. and Gu, W. (2020) Design, Synthesis, and Anticancer Evaluation of Novel Indole Derivatives of Ursolic Acid as Potential Topoisomerase II Inhibitors. International Journal of Molecular Sciences, 21, Article 2876. https://doi.org/10.3390/ijms21082876
[31]
Nemr, M.T.M., Sonousi, A. and Marzouk, A.A. (2020) Design, Synthesis and Antiproliferative Evaluation of New Tricyclic Fused Thiazolopyrimidines Targeting Topoisomerase II: Molecular Docking and Apoptosis Inducing Activity. Bioorganic Chemistry, 105, Article ID: 104446. https://doi.org/10.1016/j.bioorg.2020.104446
[32]
Arencibia, J.M., Brindani, N., Franco-Ulloa, S., Nigro, M., Kuriappan, J.A., Ottonello, G., Bertozzi, S.M., Summa, M., Girotto, S., Bertorelli, R., Armirotti, A. and De Vivi, M. (2020) Design, Synthesis, Dynamic Docking, Biochemical Characterization, and in vivo Pharmacokinetics Studies of Novel Topoisomerase II Poisons with Promising Antiproliferative Activity. Journal of Medicinal Chemistry, 63, 3508-3521. https://doi.org/10.1021/acs.jmedchem.9b01760
[33]
Infante Lara, L., Sledge, A., Laradji, A., Okoro, C.O. and Osheroff, N. (2017) Novel Trifluoromethylated 9-Amino-3, 4-Dihydroacridin-1(2H)-Ones Act as Covalent Poisons of Human Topoisomerase IIα. Bioorganic and Medicinal Chemistry Letter, 27, 586-589. https://doi.org/10.1016/j.bmcl.2016.12.011
[34]
Deng, R., Li, W., Guan, Z., Zhou, J.M., Wang, Y., Mei, Y.P., Li, M.T., Feng, G.K., Huang, W., Liu, Z.C., Han, Y., Zeng, Y.X. and Zhu, X.F. (2006) Acetylcholinesterase Expression Mediated by c-Jun-NH2-Terminal Kinase Pathway during Anticancer Drug-Induced Apoptosis. Oncogene, 25, 7070-7077. https://doi.org/10.1038/sj.onc.1209686
[35]
Yang, X., Li, W., Prescott, E.D., Burden, S.J. and Wang, J.C. (2000) DNA Topoisomerase IIβ and Neural Development. Science, 287, 131-134. https://doi.org/10.1126/science.287.5450.131
[36]
Kozurkova, M., Hamulakova, S., Gazova, Z., Paulikova, H. and Kristian, P. (2011) Neuroactive Multifunctional Tacrine Congeners with Cholinesterase, Anti-Amyloid Aggregation and Neuroprotective Properties. Pharmaceuticals, 4, 382-418. https://doi.org/10.3390/ph4020382
[37]
Mabb, A.M., Kullmann, P.H., Twomey, M.A., Miriyala, J., Philpot, B.D. and Zylka, M.J. (2014) Topoisomerase 1 Inhibition Reversibly Impairs Synaptic Function. Proceedings of the National Academy of Sciences of the United States of America, 11, 17290-17295. https://doi.org/10.1073/pnas.1413204111
